The study hit its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI
The trial enrolled patients with stage IV pancreatic cancer, where median life expectancy is just 6 to 12 months
Marks significant milestone for breakthrough biologic to treat rare blood cancers
The MAST trial is designed to test whether a single dose of pre-emptive, orally administered EBX-102-02 can protect and restore microbial diversity during transplantation
The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen
A next-generation, cell-based immunotherapy, CAR-T therapy engineers a patient’s own immune cells to detect and destroy cancer
Iza-bren met both dual primary endpoints, delivering statistically significant and clinically meaningful improvements in progression-free survival
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
Subscribe To Our Newsletter & Stay Updated
